by EpicentRx | Jan 6, 2021 | 2021, Press Releases
Company secures 10M US dollar growth capital term loan from Silicon Valley Bank (SVB) to accelerate development of immunotherapies for cancer AdAPT-001, a TGF-beta trap expressing oncolytic virus, designed to activate the immune system and improve checkpoint...
by EpicentRx | Oct 18, 2020 | Conferences
October 2020, Virtual Oral Presentation: Results of a Randomized, Open Label, Multicenter Trial Assessing the Safety, Dose and Schedule of RRx-001 (R001) in Reducing Severe Oral Mucositis (SOM) in Patients Receiving Chemoradiation (CRT) for Oral Cavity/oropharynx...
by EpicentRx | Jul 1, 2020 | 2020, Press Releases
SciClone granted exclusive license to co-develop and commercialize RRx-001 upon approval in the Greater China Region LA JOLLA, Calif., July 1, 2020 — EpicentRx Inc. (“EpicentRx”), a San Diego-based clinical cancer immunotherapy company and SciClone...
by EpicentRx | Jun 18, 2020 | Conferences
June 2020, Virtual Poster: Results of a randomized, open-label, multicenter trial to assess the safety, dose, and schedule of RRx-001(001) in reducing incidence, severity and duration of severe oral mucositis (SOM) inpatients receiving concomitant chemoradiation (CRT)...
by EpicentRx | Jun 10, 2020 | 2020, Press Releases
TORREY PINES, Calif., June 10, 2020 — EpicentRx, Inc., a clinical-stage pharmaceutical company on a mission to advance its portfolio of small molecule and virus-based immunotherapies for the treatment of patients with cancer and other diseases of high unmet need...
